Category: Uncategorized
Lehi, UT – September 12, 2024 – Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the remarkable preclinical results of its oral small molecule GLP-1 agonist, BLX-7006. In a recent study, BLX-7006 demonstrated significant weight loss efficacy, establishing it as a potential breakthrough in the global fight against obesity.
In a controlled diet-induced obesity (DIO) study conducted on mice, BLX-7006 achieved an average weight reduction of 15% over a 28-day period. These promising results are comparable to those seen with semaglutide, one of the most effective GLP-1 agonists currently available. However, BLX-7006 sets itself apart with its convenient oral administration and small molecule structure, making it a transformative prospect in weight management therapeutics.
“We are thrilled with the positive outcomes from our preclinical studies with BLX-7006,” said Dr. Hariprasad Vankayalapati, Chief Scientific Officer at Biolexis. “Our goal is to bring forward an innovative weight loss therapy that offers the same, or better, efficacy as injectable treatments but in a more convenient oral form. This is a significant step forward for patients seeking safer, more accessible treatment options.”
Key Highlights of BLX-7006:
- Oral Administration: Unlike current GLP-1 agonist treatments, which require injection, BLX-7006 is taken orally, offering greater convenience and potentially improving patient adherence.
- Small Molecule Technology: As a small molecule, BLX-7006 avoids the complexities and high costs associated with peptide-based drugs. This could streamline manufacturing processes, reduce costs, and improve drug stability.
- Reduced Side Effects: Pre-toxicology data suggest BLX-7006 is well tolerated with no observed organ toxicities when compared to current weight loss therapies, making it safer for long-term use.
- In addition to weight loss, BLX-7006 demonstrates promising efficacy in Type 2 Diabetes animal models.
Keith Marmer, Chief Business Officer at Biolexis, commented, “BLX-7006 represents a significant leap forward in weight loss treatment. It’s oral formulation and small molecule composition could offer patients an easier, more comfortable experience while delivering highly effective weight loss results. We’re excited to advance this promising therapy through IND-enabling studies, with human clinical trials scheduled for early 2025. Biolexis is excited to deliver a weight loss treatment that is widely accessible and significantly lower cost than what is currently available today.”
Biolexis Therapeutics is dedicated to addressing the global obesity epidemic through scientific innovation. The company continues to explore ways to deliver effective, accessible, and safe weight loss treatments to patients around the world.
For more information about Biolexis and its cutting-edge research, contact:
Kyle Medley
Director of Business Development
Email: kmedley@biolexistx.com
Led by Clarke Capital, the New Funding Round Will Accelerate the Company’s Drug Discovery Pipeline
American Fork, UT – November 29, 2023
Biolexis, Inc., a clinical stage AI-driven drug discovery company, announced today the successful closure of a $10 million Series A funding round. The investment was led by Clarke Capital, a prominent institutional investor and alternative investment firm.
The new funding will advance Biolexis’ development pipeline which includes a range of promising metabolic drug candidates. These drugs have the potential to tackle various metabolic disorders that affect millions of people worldwide and are linked to significant health complications such as obesity and diabetes.
“This financial backing from Clarke Capital is a testament to the potential of our metabolic drug portfolio,” said David Bearss, CEO of Biolexis. “Our science is on point and our team is ready to tackle the unmet needs within the metabolic disorder spectrum. With Clarke Capital’s support, we’re in a strong position to accelerate our drug development pipeline and move closer to bringing our solutions to patients.”
The Series A funding marks a significant milestone for Biolexis but also marks Clarke’s return to partner with Drs. Bearss and Vankayalapati, having been a major investor in their first company, Montigen Pharmaceuticals, a decade and a half ago before it was sold to a publicly traded company. The reteaming will allow the company to expand its operations and accelerate the clinical development of its key drug candidates.
With the prevalence of metabolic diseases on the rise and current treatments in limited supply, the need for new and effective treatment options is more urgent than ever.
“At Clarke Capital, we’re committed to investing in companies poised to make a significant impact on healthcare,” said James Clarke, CEO of Clarke Capital. “Biolexis’ impressive approach to addressing metabolic disorders and other treatment-resistant conditions has the potential to change lives. We are overjoyed to support their mission and look forward to seeing the results of their groundbreaking work.”
To date, Drs. Bearss and Vankayalapati have filed more than 20 Investigational New Drugs (INDs) and have secured more than 100 patents.
About Biolexis
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules that target unmet needs and are focused on metabolic diseases.
About Clarke Capital
Clarke Capital is an alternative asset investment firm with a robust portfolio of successful companies. Clarke takes a “hands on” approach when partnering with visionary entrepreneurs with an aim to create and grow high-potential, industry transformative companies.